CORE--MELANOMA FACILITY

核心——黑色素瘤设施

• 批准号: 6300086
• 负责人: STUART R LESSIN
• 金额: $ 27.67万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-02-04 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6300086
• 关键词: biomedical facility; biomedical resource; biopsy; cancer information system; cancer registry /resource; clinical research; human subject; melanoma; pathology; tissue resource /registry

The Melanoma Core has continuously approved and funded by the NCI Core Grant since 1981. The Core is of central importance to cancer investigators actively involved in basic, translational, clinical and epidemiological investigation of melanoma and its precursor lesions. It provides the integrated resources, specialized services and facilities required to serve a comprehensive, multi-disciplinary research effort directed at both understanding melanoma at a fundamental level and developing more effective diagnostic, treatment and prevention strategies. Most of the research conducted by members of the Cancer Center's Melanoma Program requires the use of the Melanoma Core's resources. The Core also serves researchers investigating analogous systems. During the current project period, users have successfully competed for a new P01 and the competitive renewal application for a long-standing P01 (pending). The Melanoma Core supports basic scientists, such as Meenhard Herlyn, DVM (Melanoma Program) and Dorothee Herlyn, DVM (Immunobiology and Melanoma Programs), translational and clinical researchers, such as Dupont Guerry, MD (Melanoma and Clinical Investigations Programs) Lynn Schuchter, MD (Clinical Investigations and Melanoma Programs), Stephen Eck, MD, PhD (Gene Therapy in Cancer Program), Douglas Fraker, MD (Clinical Investigations and Melanoma Program) and Brian Czerniecki, MD, PhD (Melanoma and Clinical Investigations Programs), as well as cancer control investigators, such as Timothy Rebbeck, PhD (Cancer Epidemiology, Melanoma and Breast Cancer Programs). During the current project period, the Melanoma Core has supported the research projects by 17 Cancer Center members totaling $4.7 million in peer-reviewed funding (annual total costs), or $3.4 million in annual direct costs. Four investigators (Czerniecki, Ganguly, Halpern and Rebbeck) have also received five Cancer Center pilot projects that relied on the Core. At the time of the last competitive renewal, this core was commended for being "one of the most cost-effective and efficient core services in the Cancer Center for the enhancement of research productivity." Usage by Cancer Center members with peer reviewed funding is 97% of total core usage, and usage by all Cancer Center members is 100% of total usage.

自1981年以来，黑色素瘤核心一直由NCI核心赠款批准和资助。该核心对于积极参与黑色素瘤及其前体病变的基础、转化、临床和流行病学研究的癌症研究者至关重要。它提供所需的综合资源，专业服务和设施，以服务于全面的，多学科的研究工作，旨在了解黑色素瘤的基本水平，并制定更有效的诊断，治疗和预防策略。癌症中心黑色素瘤项目成员进行的大多数研究都需要使用黑色素瘤核心的资源。Core还为研究类似系统的研究人员提供服务。在当前项目期间，用户成功竞争了新的P01和长期P01（待定）的竞争性续订申请。黑色素瘤核心支持基础科学家，如Meenhard Herlyn，DVM（黑色素瘤项目）和Dorothee Herlyn，DVM（免疫生物学和黑色素瘤项目），转化和临床研究人员，如Dupont Guerry，MD（黑色素瘤和临床研究项目）林恩Schuchter，医学博士（临床研究和黑色素瘤项目），Stephen Eck，MD，PhD（癌症基因治疗项目），医学博士道格拉斯弗雷克（临床研究和黑色素瘤项目）和Brian Czerniecki，MD，PhD（黑色素瘤和临床研究计划），以及癌症控制研究人员，如蒂莫西Rebbeck，博士（癌症流行病学，黑色素瘤和乳腺癌计划）。在本项目期间，黑色素瘤核心支持了17个癌症中心成员的研究项目，共获得470万美元的同行评审资金（年度总成本），或340万美元的年度直接成本。四名研究人员（Czerniecki，Ganguly，Halpern和Rebbeck）也收到了五个依赖于核心的癌症中心试点项目。在上一次竞争性更新时，该核心被称赞为“癌症中心提高研究生产力的最具成本效益和效率的核心服务之一。“癌症中心成员使用同行评审资金是97%的总核心使用量，所有癌症中心成员的使用量是100%的总使用量。